
CAP-CMV appoints Albrecht Läufer as chief executive
pharmafile | March 28, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Albrecht Läufer, CAP-CMV, cevec
Biotech firm CAP-CMV which is a spin-out of CEVEC Pharmaceuticals has appointed industry veteran Dr Albrecht Läufer as its chief executive.
The firm focusses exclusively on the development of a novel vaccine protecting against human Cytomegalovirus (HCMV) infection, and Läufer joins as the founder and chief executive of Corvay Consulting in Hannover.
Läufer was vice president Lignocellulose Conversion at Direvo Industrial Biotechnology in Köln from 2011 to 2013, and also head of business development at Rhein Biotech in Düsseldorf from 2008 to 2013.
In 2002 Läufer co-founded Vakzine Projekt Management and was its chief executive from 2003 to 2008. Prior to this from 1997 to 2003 he was regional director at Solvay Pharmaceuticals heading operations in Canada, Australia, MENA and Asia.
Läufer was chief executive of Solvay Enzymes from 1993 to 1996 and started his biotech career back in 1985 with Rütgerswerke, leaving the firm in 1993.
Joachim Rautter, managing partner at the company’s owners PVP, and speaker of CAP-CMV’s advisory board says: “We now welcome Albrecht and wish him success in taking forward CAP-CMV on its growth path”.






